Oncology Reading List

Web Resources

National Comprehensive Cancer Network - requires registration (free)
National Cancer Institute - PDQ, open access
Chemoregimen - not always up-to-date
Adjuvant Online - requires registration (free)

Hodgkin Lymphoma

Prognosis

Hasenclever D. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. NEJM 1998; 339: 1506.

Treatment

Schulz H. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group. Blood 2008; 111:109.

Gianni AM et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin's lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. 2008 ASCO annual meeting. Abstract 8506.

Dann EJ. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905.

Diehl V. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Eng J Med 2003; 348:2386.

Horning SJ. Assessment of the Stanfod V regimen consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 2000; 18:972.

Canellos GP. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. NEJM 1992; 327:1478.